Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...

Pove was generally safe and well tolerated with adverse events (AEs) that were mostly mild or moderate in severity. There were no serious adverse events related to povetacicept. The safety data is ...

CRISPR Therapeutics CRSP reported a third-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...

Union Education Minister Dharmendra Pradhan has inaugurated an AI incubation centre at the Delhi Public School in RK Puram, ...

Writers debate the causes of the current health care crisis, attributing blame to either Democratic or Republican policies.

This collaboration is geared towards enhancing digital transformation in the insurance industry by employing AI, automation ...

Geisinger Chris Beck, an experienced government affairs leader at the state, federal and health system level, will serve as ...